Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Patent
1995-06-07
1999-01-19
Nutter, Nathan M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
514170, 514177, 514179, 514964, 514965, 424457, 424478, A61K 3743, C07J 4100
Patent
active
058613870
ABSTRACT:
Methods of treatment and prevention of estrogen-related diseases, and of fertility control, include low dose (e.g. less than 50 nanomolar serum concentration) administration of certain anabolic steroids, progestins and other substantially non-masculinizing androgenic compounds. Sustained release formulations substantially free of organic solvent, and sustained release formulations for maintaining low serum levels of androgen are disclosed.
REFERENCES:
patent: 3773919 (1973-11-01), Boswell
patent: 4071622 (1978-01-01), Johnson
patent: 4107071 (1978-08-01), Bayless
patent: 4166800 (1979-09-01), Fong
patent: 4472382 (1984-09-01), Labrie
patent: 4522831 (1985-06-01), Chatterton, Jr.
patent: 4624665 (1986-11-01), Nuwayser
patent: 4659695 (1987-04-01), Labrie
patent: 4736849 (1988-04-01), Leonard et al.
patent: 4760053 (1988-07-01), Labrie
patent: 4775660 (1988-10-01), Labrie
patent: 4775661 (1988-10-01), Labrie
patent: 4818542 (1989-04-01), DeLuca
patent: 4826831 (1989-05-01), Plunkett
patent: 4863744 (1989-09-01), Urguhart et al.
patent: 4987268 (1991-01-01), Rauleder
patent: 5023080 (1991-06-01), Gupta
patent: 5043331 (1991-08-01), Hirvonen
patent: 5362720 (1994-11-01), Labrie
patent: 5434146 (1995-07-01), Labrie et al.
Maass, H. et al., J. Ster. Biochem. 5: 743-749 (1975).
Kennedy et al., Cancer, 21: 197-201 (1967).
Odell and Swerdcoff, West. J. Med. 124:446-475 (1976).
Raynaud, et al., J. Steroid Biochem 12: 143-157 (1980).
Poulin, et al., Breast Cancer Research and Treatment 12:213-325 (1988).
Poulin, et al., Breast Cancer Research and Treatment 13:161-172 (1989).
Young, et al., Am. J. Obstet. Gynecol. 137(3):284-292 (1980).
Janne, et al., Phmaracological Reviews 36(2):35S-42S (1984).
Poulin, et al., Endocrinology 125(1):392-399 (1989).
Chem. Abstr. 97(4):28542e (Jul. 26, 1982).
The Merck Index No. 5677, p. 909; No. 5687, p. 910 (1989).
The Merck Index No. 7486, p. 1188 Pizotyline (1989).
Wink and Felts, Calcif. Tissue Res. 32:77-82 (1986).
Wise, et al., Biology and Medicine pp. 237-270 (1979).
Young et al., Am. J. Obstet. Gynecol. 137:284-292 (1980).
Adair, et al., Ann. Surg. 123:1023-1035 (1946).
Adair, et al., JAMA 140:1193-2000 (1949).
Adair, Surg. Gynecol. Obstet. 84:719-722 (1947).
Allegra et al., Cancer Res. 39:1447-1454 (1979).
Aloia et al., Arch. Int. Med. 143:1700-1704 (1983).
Anderson, et al., Contraception 13:375-394 (1976).
Baker (1987) Controlled release of biologically active active agents.
Beck, et al., Adv. in Human Fert. & Reprod. Endo., pp. 175-199 (1983).
Blossey et al., Cancer 54:1208-1215 (1984).
Blumenschein, Semin. Oncol. 10:7-10 (1983).
Centola, Cancer Res. 45:6264-6267 (1985).
Colvard, et al., Proc. Natl. Acad. Sci. 86:854-857 (1989).
Deutsch et al., Int. J. Gynecol. Obstet. 25:217-222 (1987).
Ehrlich et al., Am. J. Obstet. Gynecol. 158:796-807 (1988).
Eriksen et al., Science 241:84-86 (1988).
Finkelstein et al., Ann. Int. Med. 106:354-361 (1987).
Gresser, et al., Contraception 17:253-267 (1978).
Hall, Fertility Regulation, Today and Tommorrow pp. 119-141 (1987).
Haller and Glick, Semin. Oncol. 13:2-8 (1986).
Hamblen, South Med. J. 50:743-750 (1987).
Hollo and Fehr, Acta Med. Hung. 20:233-247 (1964).
Hollo et al., Acta Med. Hung. 27:155-160 (1970).
Hollo et al., Lancet 1:1357 (1976).
Hortobagyi et al., Breast Cancer Res. Treatm. 5:321-326 (1985).
Horwitz, J. Steroid Biochem. 27:447-457 (1987).
Horwitz et al., Cancer Res. 38:2434-2439 (1978).
Janne and Bardin, Pharmacol. Rev. 36:35S-45S (1984).
Kitchell, et al., Methods in Enzymology 112:436-448 (1985).
Komm, et al., Science 241:81-84 (1988).
Kramer, Biometrics 12:307-310 (1956).
Labrie, et al., J. Steroid Biochem. 28(4):379-384 (1987).
Labrie et al., Fertil Steril. 28:1104-1112 (1977).
Labrie, et al., Mol. Cell Endocrinol. 68:169-179 (1990).
Larrea, et al., J. Steroid Biochem. 27:657-663 (1987).
Lea et al., Cancer Res. 49:7162-7167 (1989).
Lim (1984) Biomedical Application of Microencapsulation.
Lippman, Semin. Oncol. 10(Suppl. 4):11-19 (1983).
Lippman, et al., Cancer Res. 36:4610-4618 (1976).
MacLaughlin, et al., J. Steroid Biochem. 10:371-377.
Mattsson, Breast Cancer Res. Treatm. 3:231-235 (1983).
Muechler and Kohler, Gynenol. Invest. 8:104 (1988).
Nathanson, et al., Rec. Prog. Horm. Res. 1:261-291 (1947).
Need, Clin. Orthop. 225:273-278 (1987).
Nordin, et al., J. Clin. Endocr. Metab. 60:651-657 (1985).
Ojasso et al., J. Steroid Biochem. 27:255-269 (1987).
Perez-Palacios et al., J. Steroid Biochem. 15:125-130 (1981).
Perez-Palacois et al., J. Steroid Biochem. 19:1729-1735 (1983).
Podratz et al., Obstet. Gynecol. 66: 106-110, 1985.
Poulin, et al., Br. Cancer Res. Treatm. 17:197-210 (1990).
Poulin et al., Cancer Res. 46;4933-4937 (1986).
Preston, Obstet, Gynecol. 2: 152-157, 1965.
Pridjian et al., J. Steroid Biochem. 26: 313-319.
Rodbard & Lewald In: 2nd Karolinska Symposium, Geneva, 1970, pp. 79-103.
Said, et al., Contraception 37:1-20 (1988).
Silberberg, et al., Biochem. & Physiol. of Bone 2(2):401-484 (1971).
Sledge & McGuire, Cancer Res. 38: 61-75, 1984.
Tatman et al., Eur. J. Cancer Clin. Oncol. 25: 1619-1621, 1989.
Urist & Vincent, J. Clin. Orthop. 18:199-208 (1961).
Verhas et al., Calf. Tissue Res. 39:74-77 (1986).
Vilchis, et al., J. Steroid Biochem 24:525-531 (1986).
Van Veelen et al., Cancer Chemother. Pharmacol. 15:167-170 (1985).
Albright, et al., In: The Parathyroid Glands & Metabolic Bone Disease, William & Williams Co: Baltimore, pp. 145-204 (1948).
Aloia et al., Metabolism 30:1076-1079 (1981).
Asselin et al., Cancer Res. 40:1612-1622 (1980).
Baran et al., Calif. Tissue Res. 26:103-106, 1978.
Bryan et al., Cancer 54: 2436-2440, 1984.
Bullock et al., Endocrinology 103: 1768-1782, 1978.
Chessnut et al. Metabolism 26: 267-277, 1977.
Chessnut et al., Netabolism 32:271-580, 1983.
Clavel et al., Eur. J. Cancer Clin. Oncol. 18:821-826, 1982.
Cooperative Breast Cancer Group, JAMA 188, 1069-1072, 1964.
Cremonicini et al., Acta. Eur. Fertil. 7:248-314, 1976.
Cusan et al., J. Am. Acad. Dermatol. 23:462-469, 1990.
Dauvois & Labrie, Cancer Res. 51:3131-3151 (1991).
Dauvois, et al., Breast Cancer Res. Treatment 14:299-306 (1989).
Dequaker & Guesens, Acta Endocrinology 271 (Suppl):45-52, 1985.
Dhem. A., Ars-Piret N., Waterschoot MP (1980) Curr. Med. Res. Opin. 6: 606-613.
Dickson & Lippman, Endocr. Rev. 8:29-43, 1987.
Dixon et al., Clinical Endocrinology 30: 271-277, 1989.
Earl et al., Clin. Oncol. 10:103-109, 1984.
Engel et al., Cancer Res. 358: 3352-3364, 1978.
Engelsman et al., British J. Cancer 30: 177-181, 1975.
Ferriman & Gallwey, J.P. Clin Endocrimol. Metab 21: 1440-1447, 1961.
Finkelstein et al., J. Clin. Endocr. Metab. 69:776-783, 1989.
Francis, et al., Bone 7: 261-268 (1986).
Foresta et al., Horm. Metab. Res. 15:206-207, 1983.
Foresta et al., Horm. Metab. Res. 15:56-57, 1983.
Goldenberg et al., JAMA 223: 1267-1268, 1973.
Greenspan et al., Ann. Int. Med. 110:526-531, 1989.
Greenspan et al., Ann Int. Med. 104:777-782, 1986.
Harrison et al., Metabolism 20:1107-1118, 1971.
Hollo et al., Lancet 2:1205, 1971.
Hilf. R., Anabolic-Androgenic Steroids and Experimental Tumors In: Handbook of Experimental Pharmacology, vol. 43, Anabolic-Androgenic Steroids, Springer-Verlag, Berlin 43 (1976) 191-210 and p. 725.
Johnson et al. Semin. Oncol. 13(suppl):15-19, 1986.
Kennedy, Hormone Therapy in Cancer Geriatrics 25: 106-112, 1970.
Klijn et al., J. Steroid Biochem. 20: 1381, 1984.
Krabbe et al., Arch. Dis. Child. 54, 950-953, 1979.
Krabbe et al., Arch. Pediat. Scand. 73:750-755, 1984.
Labrie, et al., Fertil. Steril. 31:29-34, 1979.
Lafferty et al., Ann. J. Med. 36: 514-528, 1964.
Lamb, Am. J. Sports Medicine 121, 31-38, 1984.
Lippman et al., Cancer 38: 868-874, 1976.
Lucas, Obestet. Gynecol. Surv. 29: 507-528, 1974.
Luthy et al., J. Steroid Biochem. 31: 845-852, 1988.
Mack et al., N. Engl. J. Medicine 294: 1262-1267, 1976.
Manni et al., Cancer 48: 2507-2509, 1981.
Manni et al., Endocr., Rev. 7: 89-94 (1986).
McDermott & Kidd. End. Rev. 8:377-390, 1987.
Miller et al., Eur. J. Oncol. 21: 539-542, 1985.
Need et al., Mineral Electrolyte Metabolism 11:35, 1985.
Nicholson et al., J. Steroid Biochem. 23: 843-848, 19
Labrie Fernand
Lepage Martin
Endorecherche Inc.
Nutter Nathan M.
LandOfFree
Controlled release systems and low dose androgens does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Controlled release systems and low dose androgens, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Controlled release systems and low dose androgens will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1246761